Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... September 30, 2014 Dr. Karl R.O.S. ... pain program of care that is dramatically improving ... His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, multi-dimensional ... It also addresses sources of inflammation, neurology of the ... “neurokinetic chain” from the brain to the spine, to ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Medicare should ... at high risk for the disease, a coalition of ... The coalition, which includes the Lung Cancer Alliance, the ... the American Cancer Society and the American Society of ... Monday to the U.S. Centers for Medicare & Medicaid ...
Breaking Medicine News(10 mins):Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... , , NEW YORK , ... today applauded the Social Security Administration for including early-onset Alzheimer,s ... approval for disability benefits, rather than have individuals go through ... counts for people with Alzheimer,s disease," said Eric J. ...
... attend school should not be given doctors, sick notes. ... (Dtsch Arztebl Int 2010; 107[4]), child and adolescent ... school avoidance and describe measures to tackle the problem. ... frequently and is accompanied by psychiatric symptoms. Children typically ...
... treatment, researchers say, , THURSDAY, Feb. 11 (HealthDay News) ... gene that makes breast cancer more aggressive, according to ... say, could lead to better diagnostic tests for breast ... researchers found that the hormone prolactin, which normally stimulates ...
... Implications ... Conference and Research Symposium. , ... 11, 2010 -- Stuttering may be the result of a glitch in the day-to-day process by ... study in the Feb. 10 Online First issue of the New England Journal of Medicine. , ...
... , ... is offering a limited number of grants to parents of children with autism and other ... in Philadelphia, May 20-22, 2010. , ... (PRWEB) February 11, 2010 -- The Autism Science Foundation , a not-for-profit organization ...
... , More than 3 million people have texted " ... , WASHINGTON , Feb. 11 ... to the American Red Cross Haiti Relief and Development Fund by sending the ... in mobile giving for the ongoing relief efforts. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ...
Cached Medicine News:Health News:Alzheimer's Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimer's Disease 2Health News:Hormone May Prevent Aggressive Breast Cancer 2Health News:Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association 2Health News:Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association 3Health News:Autism Science Foundation Offers IMFAR Grants to Autism Stakeholders 2Health News:Autism Science Foundation Offers IMFAR Grants to Autism Stakeholders 3Health News:Red Cross Raises More Than $32 Million Via Mobile Giving Program 2Health News:Red Cross Raises More Than $32 Million Via Mobile Giving Program 3Health News:Red Cross Raises More Than $32 Million Via Mobile Giving Program 4Health News:Red Cross Raises More Than $32 Million Via Mobile Giving Program 5Health News:Red Cross Raises More Than $32 Million Via Mobile Giving Program 6
(Date:9/30/2014)... 30, 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... that the company,s Bridgewater, New Jersey ... Food and Drug Administration (FDA) relating to an inspection ... to Sculptra Aesthetic injectable, which was divested to Galderma ... management of Valeant,s contract manufacturers (rather than Valeant,s own ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Corporation (NYSE: BSX ) is further supporting the ... American Urogynecologic Society,s new patient website, Take the Floor ... Annual Scientific Meeting, September 14 – 17 in Providence, RI. ... to serve as an interactive, online community for female patients ...
... Sept. 15, 2011 Actavis, an international generic pharmaceutical ... of Levetiracetam Extended-Release Tablets, a generic equivalent of Keppra ... XR® had US total sales of approximately $161 million ... to IMS Health.   About Actavis: ...
Cached Medicine Technology:Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders 2Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders 3Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders 4Actavis Launches Generic Keppra XR® Tablets in the U.S. 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: